251 related articles for article (PubMed ID: 33828551)
1. Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.
Lutterotti A; Hayward-Koennecke H; Sospedra M; Martin R
Front Immunol; 2021; 12():640935. PubMed ID: 33828551
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific therapies in MS - Current concepts and novel approaches.
Lutterotti A; Sospedra M; Martin R
J Neurol Sci; 2008 Nov; 274(1-2):18-22. PubMed ID: 18599087
[TBL] [Abstract][Full Text] [Related]
3. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.
Fukaura H; Kent SC; Pietrusewicz MJ; Khoury SJ; Weiner HL; Hafler DA
J Clin Invest; 1996 Jul; 98(1):70-7. PubMed ID: 8690806
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis.
Docampo MJ; Lutterotti A; Sospedra M; Martin R
Front Immunol; 2021; 12():787498. PubMed ID: 35069562
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific tolerization approaches in multiple sclerosis.
Lutterotti A; Martin R
Expert Opin Investig Drugs; 2014 Jan; 23(1):9-20. PubMed ID: 24151958
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific therapies in multiple sclerosis.
Sospedra M; Martin R
Int Rev Immunol; 2005; 24(5-6):393-413. PubMed ID: 16318988
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
Li V; Binder MD; Purcell AW; Kilpatrick TJ
J Neuroimmunol; 2024 May; 390():578347. PubMed ID: 38663308
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
Steinman L; Ho PP; Robinson WH; Utz PJ; Villoslada P
Curr Opin Immunol; 2019 Dec; 61():46-53. PubMed ID: 31476445
[TBL] [Abstract][Full Text] [Related]
9. [Current therapy of multiple sclerosis. Oral tolerance induction to myelin antigens].
Voltz R; Hohlfeld R
Nervenarzt; 1993 Jun; 64(6):411-2. PubMed ID: 8332235
[No Abstract] [Full Text] [Related]
10. Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
Wildner P; Selmaj KW
J Neuroimmunol; 2017 Oct; 311():49-58. PubMed ID: 28803660
[TBL] [Abstract][Full Text] [Related]
11. Treatment of autoimmune disease by oral tolerance to autoantigens.
Whitacre CC; Gienapp IE; Meyer A; Cox KL; Javed N
Clin Immunol Immunopathol; 1996 Sep; 80(3 Pt 2):S31-9. PubMed ID: 8811061
[TBL] [Abstract][Full Text] [Related]
12. Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.
Verbeek R; van der Mark K; Wawrousek EF; Plomp AC; van Noort JM
Immunology; 2007 Jul; 121(3):416-26. PubMed ID: 17386078
[TBL] [Abstract][Full Text] [Related]
13. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.
Zubizarreta I; Flórez-Grau G; Vila G; Cabezón R; España C; Andorra M; Saiz A; Llufriu S; Sepulveda M; Sola-Valls N; Martinez-Lapiscina EH; Pulido-Valdeolivas I; Casanova B; Martinez Gines M; Tellez N; Oreja-Guevara C; Español M; Trias E; Cid J; Juan M; Lozano M; Blanco Y; Steinman L; Benitez-Ribas D; Villoslada P
Proc Natl Acad Sci U S A; 2019 Apr; 116(17):8463-8470. PubMed ID: 30962374
[TBL] [Abstract][Full Text] [Related]
14. Immune tolerance to myelin proteins.
Seamons A; Perchellet A; Goverman J
Immunol Res; 2003; 28(3):201-21. PubMed ID: 14713715
[TBL] [Abstract][Full Text] [Related]
15. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.
Willekens B; Presas-Rodríguez S; Mansilla MJ; Derdelinckx J; Lee WP; Nijs G; De Laere M; Wens I; Cras P; Parizel P; Van Hecke W; Ribbens A; Billiet T; Adams G; Couttenye MM; Navarro-Barriuso J; Teniente-Serra A; Quirant-Sánchez B; Lopez-Diaz de Cerio A; Inogés S; Prosper F; Kip A; Verheij H; Gross CC; Wiendl H; Van Ham MS; Ten Brinke A; Barriocanal AM; Massuet-Vilamajó A; Hens N; Berneman Z; Martínez-Cáceres E; Cools N; Ramo-Tello C;
BMJ Open; 2019 Sep; 9(9):e030309. PubMed ID: 31501122
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis.
Hafler DA; Kent SC; Pietrusewicz MJ; Khoury SJ; Weiner HL; Fukaura H
Ann N Y Acad Sci; 1997 Dec; 835():120-31. PubMed ID: 9616767
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of the immune response in autoimmune demyelination.
Oksenberg JR
West J Med; 1994 Sep; 161(3):255-9. PubMed ID: 7975563
[TBL] [Abstract][Full Text] [Related]
18. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[TBL] [Abstract][Full Text] [Related]
19. Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells.
Leon MA; Wemlinger SM; Larson NR; Ruffalo JK; Sestak JO; Middaugh CR; Cambier JC; Berkland C
Mol Pharm; 2019 Apr; 16(4):1563-1572. PubMed ID: 30681867
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis.
de Andrade Pereira B; Fraefel C; Hilbe M; Ackermann M; Dresch C
Gene Ther; 2013 May; 20(5):556-66. PubMed ID: 22951454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
